Heteroaryl substituted ansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride

Applied Organometallic Chemistry

Volumn 19, Issue 3, 2005, Pages 293-300

  Rehmann, Franz Josef K ^a   Cuffe, Laurence P ^a   Mendoza, Oscar ^a   Rai, Dilip K ^a   Sweeney, Nigel ^a   Strohfeldt, Katja ^a   Gallagher, William M ^a   Tacke, Matthias ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Anti cancer drug; cis platinum; DFT calculations; Fulvene; LLC PK; Titanocene

Indexed keywords

CONCENTRATION (PROCESS); SUBSTITUTION REACTIONS; SYNTHESIS (CHEMICAL); TITANIUM COMPOUNDS; TUMORS;

ANTI-CANCER DRUGS; CARCINOMA CELLS; TITANIUM DICHLORIDE;

DRUG DOSAGE;

1 METHYL 2 PYRROLYLFULVENE; 2 FURYLFULVENE; 2 THIOPHENYLFULVENE; [1,2 BIS(CYCLOPENTADIENYL) 1,2 BIS(1 METHYL 2 PYRROLYL)ETHANEDIYL]TITANIUM DICHLORIDE; [1,2 BIS(CYCLOPENTADIENYL) 1,2 DI (2 FURYL)ETHANEDIYL]TITANIUM DICHLORIDE; ANTINEOPLASTIC AGENT; TITANOCENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; KIDNEY CARCINOMA; NONHUMAN;

EID: 15444367843     PISSN: 02682605     EISSN: None     Source Type: Journal    
DOI: 10.1002/aoc.864     Document Type: Article

References (25)

1. Gelasco A, Lippard SJ. Top. Biol. Inorg. Chem. 1999; 1: 1.
2. Jamieson ER, Lippard SJ. Chem. Rev. 1999; 99: 2467.
3. Farrell N, Qu Y, Roberts JD. Top. Biol. Inorg. Chem. 1999; 1: 99.
4. Köpf-Maier P, Köpf H. Chem. Rev. 1987; 87: 1137.
5. Köpf-Maier P, Köpf H. Struct. Bonding 1988; 70: 105.
6. Christodoulou CV, Ferry DR, Fyfe DW, Young A, Doran J, Sheehan TM, Eliopoulos A, Hale K, Baumgart J, Saß G, Kerr DJ. J. Clin. Oncol. 1998; 16: 2761.
7. Korfel A, Scheulen ME, Schmoll HJ, Grundel O, Harstrick A, Knoche M, Fels M, Skorzec M, Bach F, Baumgart J, Saß G, Seeber S, Thiel E, Berdel WE. Clin. Cancer Res. 1998; 4: 2701.
8. Lummen G, Sperling H, Luboldt H, Otto T, Rubben H. Cancer Chemother. Pharmacol. 1998; 42: 415.
9. Kröger N, Kleeberg UR, Mross K, Edler L, Saß G, Hossfeld DK. Onkologie 2000; 23: 60.
10. Mokdsi G, Harding MM. Metal-Based Drugs 1998; 5: 207.
11. Allen OR, Croll L, Gott AL, Knox RJ, McGowan PC. Organometallics 2004; 23: 288.
12. Boyles RJ, Baird MC, Campling BG, Jain N. J. Inorg. Biochem. 2001; 84: 159.
13. Teuber R, Linti G, Tacke M. J. Organometal. Chem. 1997; 545-546: 105.
14. Hartl F, Cuffe L, Dunne JP, Fox S, Mahabiersing T, Tacke M. J. Mol. Struct. 2001; 559: 331.
15. Tacke M, Dunne JP, Fox S, Linti G, Teuber R. J. Mol. Struct. 2001; 570: 197.
16. Fox S, Dunne JP, Dronskowski Schmitz D, Tacke M. Eur. J. Inorg. Chem. 2002; 3039.
17. Eisch JJ, Shi X, Owuor FA. Organometallics 1998; 17: 5219.
18. Eisch JJ, Owuor FA, Shi X. Organometallics 1999; 18: 1583.
19. Kane KM, Shapiro PJ, Vij A, Cubbon R, Rheingold AL. Organometallics 1997; 16: 4571.
20. Fox S, Dunne JP, Tacke M, Gallagher JF. Inorg. Chim. Acta 2004; 357: 225.
21. Tacke M, Allen LT, Cuffe LP, Gallagher WM, Lou Y, Mendoza O, Müller-Bunz H, Rehmann FJK, Sweeney N. J. Organometal. Chem. 2004; 689: 2242.
22. Stone KJ, Little RD. J. Org. Chem. 1984; 49: 1849.
23. Tan T, Fletscher JJ, McGlinchey MJ. J. Chem. Soc. Chem Commun. 1975; 771.
24. Rinehart KL, Frerichs AK, Kittle PA, Westman LF, Gustafson DH, Pruett RL, McMahon JE. J. Am. Chem. Soc. 1960; 82: 1111.
25. Mosmarm T. J. Immunol. Methods 1983; 65: 55.